These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 16484125

  • 1. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW.
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
    Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP.
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
    [Abstract] [Full Text] [Related]

  • 4. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S.
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [Abstract] [Full Text] [Related]

  • 5. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
    Shahidi S, Ashrafi F, Mohammadi M, Moeinzadeh F, Atapour A.
    Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.
    Leung TF, Chu Y, Lee V, Cheng FW, Leung WK, Shing MM, Li CK.
    Hemoglobin; 2009 Jan; 33(5):361-9. PubMed ID: 19814683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 9. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 10. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J, Brown C, Moore AEB, Min SS, Hampson G.
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients.
    Krajcovicova A, Hlavaty T, Killinger Z, Miznerova E, Toth J, Letkovsky J, Nevidanska M, Cierny D, Koller T, Zelinkova Z, Huorka M, Payer J.
    J Crohns Colitis; 2014 Dec; 8(12):1693-701. PubMed ID: 25175812
    [Abstract] [Full Text] [Related]

  • 13. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease.
    Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR.
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):538-45. PubMed ID: 18030230
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
    Angthong C, Rodjanawijitkul S, Samart S, Angthong W.
    Acta Orthop Traumatol Turc; 2013 Nov; 47(5):318-22. PubMed ID: 24164940
    [Abstract] [Full Text] [Related]

  • 16. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M, Bultink IE, Dijkmans BA, Lems WF.
    Osteoporos Int; 2005 Nov 30; 16(11):1432-5. PubMed ID: 15883662
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.